Antiretroviral treatment in pregnancy: A six-year perspective on recent trends in prescription patterns, viral load suppression, and pregnancy outcomes

AIDS Patient Care and STDs

Volumn 23, Issue 7, 2009, Pages 513-520

  Baroncelli, Silvia ^a   Tamburrini, Enrica ^b   Ravizza, Marina ^c   Dalzero, Serena ^c   Tibaldi, Cecilia ^d   Ferrazzi, Enrico ^c   Anzidei, Gianfranco ^e   Fiscon, Marta ^f   Alberico, Salvatore ^g   Martinelli, Pasquale ^h   Placido, Giuseppina ⁱ   Guaraldi, Giovanni ^j   Pinnetti, Carmela ^b   Floridia, Marco ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

^g Policlinic Hospital   (Italy)

^h UNIVERSITY OF NAPLES FEDERICO II   (Italy)

ⁱ SPIRITO SANTO HOSPITAL   (Italy)

^j UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; APGAR SCORE; ARTICLE; BIRTH DEFECT; BIRTH WEIGHT; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SURVEILLANCE; DRUG SUBSTITUTION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSURVEILLANCE; MAJOR CLINICAL STUDY; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURE LABOR; PRESCRIPTION; THIRD TRIMESTER PREGNANCY; VIRUS LOAD;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; ITALY; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; RETROSPECTIVE STUDIES; VIRAL LOAD; YOUNG ADULT;

EID: 69249153822     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2008.0263     Document Type: Article

References (61)

1. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society - USA. JAMA 1996;276:146-154.
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. January 29, 2008; 1-128. (Last accessed May 11, 2009).
3. U.S. Food and Dug Administration: Drugs used in the treatment of HIV infection. www.fda.gov/oashi/aids/virals.html 2008 (Last accessed May 11, 2009).
4. Spira R, Marimoutou C, Binquet C, Lacoste D, Dabis F. Rapid change in the use of antiretroviral agents and improvement in a population of HIV-infected patients: France, 1995-1997. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA). J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:358-364
5. Sackoff JE, McFarland JW, Shin SS. Trends in prescriptions for highly active antiretroviral therapy in four New York City HIV clinics. J Acquir Immune Defic Syndr 2000;23:178-183.
6. Jiménez-Nácher I, García B, Barreiro P, Rodriguez-Novoa S et al. Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. J Antimicrob Chemother 2008;62:816-822.
7. Falster K, Gelgor L, Shaik A, et al. Trends in antiretroviral treatment use and treatment response in three Australian states in the first decade of combination antiretroviral treatment. Sex Health 2008;5:141-154. (Pubitemid 351786449)
8. Sighinolfi L, Torti C, Zeni C et al. Evolution of Antiretroviral Prescription and Response over a Period of 8 years: An Italian Multicentre Observational Prospective Cohort Study. Infection 2008;36:244-249.
9. Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet 2004;43:1071-1087.
10. Roustit M, Jlaiel M, Leclercq P, Stanke-Labesque F. Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women. Br J Clin Pharmacol 2008;66:179-195. (Pubitemid 351991459)
11. Perinatal HIV guidelines Working Group. Public Health Service Task Force Reccomandations for Use of Antiretroviral Drugs in Pregnant HIV-infected Woman for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States. http://aidsinfo.nih.gov/contentfiles/PerinatalGL.pdf (Last accessed July 8, 2008).
12. Floridia M, Tamburrini E, Ravizza M et al. Antiretroviral therapy at conception in pregnant women with HIV in Italy: Wide range of variability and frequent exposure to contraindicated drugs. Antivir Ther 2006;11:941-946. (Pubitemid 44736187)
13. Floridia M, Ravizza M, Tamburrini E, et al. Diagnosis of HIV infection in pregnancy: data from a national cohort of pregnant women with HIV in Italy. Epidemiol Infect 2006;134: 1120-1127. (Pubitemid 44336390)
14. Scheuerle A, Covington D. Clinical review procedures for the Antiretroviral Pregnancy Registry. Pharmacoepidemiol Drug Saf 2004;13:529-536. (Pubitemid 39214031)
15. Centers for Disease Control and Prevention. HIV/AIDS Sur- DS Surveillance Report, 2006. Vol.18. Atlanta: US Department of Health and Human Services, www.cdc.gov/hiv/topics/surveillance/resources/reports/2006report/pdf/ 2006SurveillanceReport.pdf (Last accessed May 11, 2009).
16. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studies. Lancet 2008;372:293-299.
17. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002;29:484-494. (Pubitemid 34456340)
18. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005;40:458-465. (Pubitemid 40216516)
19. Martinelli P, Agangi A, Sansone M, et al. Epidemiological and clinical features of pregnant women with HIV: A 21-year perspective from a highly specialized regional center in southern Italy. HIV Clin Trials 2008;9:36-42. (Pubitemid 351214239)
20. Townsend CL, Tookey PA, Cortina-Borja M, Peckham CS. Antiretroviral therapy and congenital abnormalities in infants born to HIV-1-infected women in the United Kingdom and Ireland, 1990 to 2003. J Acquir Immune Defic Syndr 2006;42:91-94.
21. Lemaitre G, Liebig T, Thoreau Cm Fron P. Standardised statistics on immigrant inflows results, sources and methods. Organization for Economic Cooperation and Development. www.oecd.org/dataoecd/39/29/38832099.pdf. June 2007 (Last accessed May 11, 2009).
22. Hamers FF, Phillips AN. Diagnosed and undiagnosed HIV-infected populations in Europe. HIV Med 2008;9(Suppl 2): 6-12.
23. Centers for Disease Control and Prevention (CDC). Subpopulation estimates from the HIV incidence surveillance system - United States, 2006. MMWR Morb Mortal Wkly Rep 2008;57:985-989.
24. Pirillo MF, Bassani L, Germinario EA, et al. Seroprevalence of hepatitis B and C viruses among HIV-infected pregnant women in Uganda and Rwanda. J Med Virol 2007;79:1797-1801. (Pubitemid 350006301)
25. Otegbayo JA, Taiwo BO, Akingbola TS, et al. Prevalence of hepatitis B and C seropositivity in a Nigerian cohort of HIV-infected patients. Ann Hepatol 2008;7:152-156. (Pubitemid 351845527)
26. Levi J. Ensuring timely access to care for people with HIV infection: A public health imperative. Am J Public Health 2002;92:339-340. (Pubitemid 34184811)
27. Girardi E, Sabin CA, Monforte AD. Late diagnosis of HIV infection: Epidemiological features, consequences and strategies to encourage earlier testing. J Acquir Immune Defic Syndr 2007;46(Suppl 1):S3-8. (Pubitemid 47312320)
28. Vento S, Lanzafame M, Pellegrino R, Apuzzo G, Lattuada E, Vallone A. Voluntary or universal HIV testing in Italy? Clin Infect Dis 2008;46:644-645.
29. Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health-Care Settings. 2006. www.cdc.gov/mmwr/preview/mmwrhtml/ rr5514a1.htm September 22, 2006. (Last accessed May 11, 2009).
30. Fundarò C, Genovese O, Rendeli C, Tamburrini E, Salvaggio E. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 2002;16:299-300. (Pubitemid 34118582)
31. Sustiva [product labelling]. Bristol-Myers Squibb Company, Princeton, NJ, 2007.
32. Jeantils V, Khuong MA, Delassus JL, et al. Efavirenz (Sustiva) in pregnancy: A study about 12 HIV patients. Gynecol Obstet Fertil 2006;34:593-596.
33. Sarner L, Fakoya A. Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. Sex Transm Infect 2002;78:58-59. (Pubitemid 34206317)
34. Side effects. FDA issues warning about d4T and ddI during pregnancy. Treatment Update 2001;12:6-7.
35. Mandelbrot L, Peytavin G, Firtion G, Farinotti R. Maternalfetal transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency virus-infected pregnant women. Am J Obstet Gynecol 2001;184:153-158. (Pubitemid 32141658)
36. Antiretroviral Pregnancy Registry Steering Commitee. Antiretroviral pregnancy registry international interim report for 1 Jan 1989-31 January 2007. Wilmington, NC Registry Coordinating Center; 2004. www.APRegistry.com (Last accessed May 11, 2009).
37. Moyle G, Sawyer W, Law M, Amin J, Hill A. Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: A meta-analysis of six prospective, randomized, comparative studies. Clin Ther 2004;26:92-97. (Pubitemid 38241526)
38. Sullivan PS, Hanson DL, Brooks JT. Impact on hemoglobin of starting combination antiretroviral therapy with or without zidovudine in anemic HIV-infected patients. J Acquir Immune Defic Syndr 2008;48:163-168.
39. Benhammou V, Tardieu M, Warszawski J, Rustin P, Blanche S. Clinical mitochondrial dysfunction in uninfected children born to HIV-infected mothers following perinatal exposure to nucleoside analogues. Environ Mol Mutagen 2007;48:173-178. (Pubitemid 46536085)
40. Foster C, Lyall H. HIV and mitochondrial toxicity in children. J Antimicrob Chemother 2008;61:8-12.
41. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006;354:251-260.
42. Masho SW, Wang CL, Nixon DE. Review of tenofoviremtricitabine. Ther Clin Risk Manag 2007;3:1097-1104.
43. Barrios A, García-Benayas T, González-Lahoz J, Soriano V. Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS 2004;18:960-963.
44. Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of anti-retroviral agents as salvage therapy: Impact on bone mineral density in HIV-infected children. Pediatrics 2006;118:e711-718. (Pubitemid 46089998)
45. Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr 2008;152:582-584.
46. Timmermans S, Tempelman C, Godfried MH, et al. Nelfinavir and nevirapine side effects during pregnancy. AIDS 2005;19:795-799. (Pubitemid 40834749)
47. European Collaborative Study; Patel D, Cortina-Borja M, Thorne C, et al. Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis 2007;44:1647-1656. (Pubitemid 46871514)
48. van Schalkwyk JE, Alimenti A, Khoo D, et al. Serious toxicity associated with continuous nevirapine-based HAART in pregnancy. Br J Obstet Gynecol 2008;115:1297-1302.
49. von Hentig N, Carlebach A, Gute P, et al. A comparison of the steady-state pharmacokinetics of nevirapine in men, non-pregnant women and women in late pregnancy. Br J Clin Pharmacol 2006;62:552-559. (Pubitemid 44571576)
50. Gingelmaier A, Kurowski M, Kastner R, et al. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS 2006;20:1737-1743. (Pubitemid 44299365)
51. Baroncelli S, Villani P, Floridia M, et al. Pre-dose and three-hour post-dose of lopinavir, nelfinavir, and nevirapine plasma levels in HIV-infected pregnant women receiving three-drug combination regimens. Ther Drug Monitor 2008; 30:604-610.
52. Lyons FE, Coughlan S, Byrne CM, et al. Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. AIDS 2005;19: 63-67. (Pubitemid 40111019)
53. Marzolini C, Rudin C, Decosterd LA, et al. Transplacental passage of protease inhibitors at delivery. AIDS 2002;16:889-893. (Pubitemid 34409012)
54. Mirochnick M, Dorenbaum A, Holland D, et al. Concentrations of protease inhibitors in cord blood after in utero exposure. Pediatr Infect Dis J 2002;21:835-838.
55. Marzolini C, Kim RB. Placental transfer of antiretroviral drugs. Clin Pharmacol Ther 2005;78:118-122.
56. Hirt D, Treluyer JM, Jullien V, et al. Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: A population study with 133 women. Antimicrob Agents Chemother 2006;50:2079-2086. (Pubitemid 43807529)
57. Villani P, Floridia M, Pirillo MF, et al. Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women. Br J Clin Pharmacol 2006;62:309-315. (Pubitemid 44215531)
58. Roche. Viracept Recall: Important Information for Patients. June 6, 2007.
59. Wensing AM, Boucher CA, van Kasteren M, van Dijken PJ, Geelen SP, Juttmann JR. Prevention of mother-to-child transmission of multi-drug resistant HIV-1 using maternal therapy with both enfuvirtide and tipranavir. AIDS 2006;20:1465-1467.
60. Lopez-Cortes LF, Ruiz-Valderas R, Rivero A, et al. Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategy. Ther Drug Monit 2007;29:171-176. (Pubitemid 46716182)
61. Ripamonti D, Cattaneo D, Maggiolo F, et al. Atazanavir plus low-dose ritonavir in pregnancy: Pharmacokinetics and placental transfer. AIDS 2007;21:2409-2415. (Pubitemid 350145172)